projected global drug discovery market size by 2030
annual growth rate by 2030
EonBio’s cell-free technology recreates some of the specific pieces of cellular machinery on silicon chips without the unwanted interferences usually found in real, living cells. This way, the complex synthesis of proteins, metabolites, and other useful biomaterials can be streamlined and scaled, including novel and more effective drugs, and new-to-nature polymers.
Capacity to produce novel and more effective drugs, in a faster and more economical way. It has the potential to drastically accelerate the pace of therapeutic innovation.
Cell-free technology may revolutionize other fields, namely manufacturing and the engineered synthetic materials field.
EonBio has been co-founded by eureKARE, Yeda, the commercial arm of the Weizmann Institute of Science, and built on the innovative research of Professor Roy Bar-Ziv’s lab.
Prof. Roy Bar-Ziv
Founder
Roy Bar-Ziv is an associate professor in the Department of Materials and Interfaces at the Weizmann Institute of Science, in Israel. His research combines physics, biology, and materials science to construct and explore cell-mimicking, artificial biological compartments on a chip. Roy Bar-Ziv was awarded the Krill Prize for Excellence in Scientific Research and is the winner of the eureKAWARDS 2021.
